Stay updated with breaking news from Brian Plummer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
Analysis of Real-World Data in People Living With HIV in the International BICSTaR Study to be Presented at EACS 2021 Also Confirm the Long-Term Efficacy and Safety Profile of Biktarvy – Gilead Sciences, Inc. today announced the company’s upcoming contributions to the 18th European AIDS Conference taking place virtually and onsite in London from October 27-30. Forty-four studies from Gilead’s HIV research and ...
- Analysis of Real-World Data in People Living With HIV in the International BICSTaR Study to be Presented at EACS 2021 Also Confirm the Long-Term Efficacy and Safety Profile of Biktarvy - Gilead
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
EMA MAA Validation Follows Submission of NDA for Lenacapavir to the U.S. FDA – – If Authorized, Lenacapavir Would be the First Capsid Inhibitor and the Only HIV-1 Treatment Option Administered Twice Yearly – Gilead Sciences, Inc. today announced that the company’s Marketing Authorization Application for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, has been fully validated and is now ...